NASDAQ:RTRX - Travere Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.25
  • Forecasted Upside: 121.09 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.23
▲ +0.25 (1.93%)
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RTRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RTRX

Analyst Price Target is $29.25
▲ +121.09% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $29.25, with a high forecast of $33.00 and a low forecast of $21.00. The average price target represents a 121.09% upside from the last price of $13.23.

This chart shows the closing price for RTRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Travere Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $33.00High
9/17/2020WedbushInitiated CoverageOutperform$33.00High
8/24/2020Bank of AmericaInitiated CoverageBuy$30.00Low
7/31/2020BarclaysReiterated RatingHold$21.00Medium
7/13/2020BMO Capital MarketsLower Price Target$34.00 ➝ $31.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$25.00Low
5/19/2020Canaccord GenuityReiterated RatingBuy$26.00High
5/12/2020BMO Capital MarketsBoost Price TargetOutperform$33.00 ➝ $34.00High
2/25/2020BarclaysDowngradeOverweight ➝ Equal Weight$19.00High
8/23/2019Jefferies Financial GroupSet Price TargetBuy$33.00N/A
8/23/2019William BlairReiterated RatingBuyHigh
8/23/2019Canaccord GenuityLower Price TargetBuy$38.00 ➝ $23.00Medium
8/23/2019BMO Capital MarketsLower Price TargetPositive ➝ Outperform$38.00 ➝ $33.00Medium
8/23/2019Nomura SecuritiesLower Price TargetBuy$57.00 ➝ $33.00Medium
8/23/2019BarclaysLower Price TargetOverweight$36.00 ➝ $20.00High
8/22/2019BMO Capital MarketsSet Price TargetBuy$38.00Low
8/22/2019JMP SecuritiesSet Price TargetBuy$32.00 ➝ $26.00Low
8/8/2019Nomura SecuritiesReiterated RatingBuy$57.00Medium
8/7/2019Canaccord GenuitySet Price TargetBuy$38.00Low
7/5/2019William BlairReiterated RatingBuyMedium
7/1/2019Canaccord GenuityBoost Price TargetBuy$37.00 ➝ $41.00High
4/22/2019BarclaysInitiated CoverageOverweight ➝ Overweight$36.00Medium
4/17/2019William BlairReiterated RatingOutperformLow
2/26/2019SVB LeerinkReiterated RatingOutperformLow
11/19/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$57.00High
10/30/2018Jefferies Financial GroupInitiated CoverageBuy$44.00High
8/17/2018Canaccord GenuityInitiated CoverageBuyHigh
4/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$44.00 ➝ $43.00High
10/6/2017BMO Capital MarketsReiterated RatingBuy$44.00N/A
4/6/2017William BlairReiterated RatingOutperformMedium
3/2/2017BMO Capital MarketsLower Price TargetOutperform$46.00 ➝ $45.00N/A
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/A
12/14/2016BMO Capital MarketsSet Price TargetBuy$46.00N/A
11/21/2016BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $46.00N/A
11/11/2016JMP SecuritiesReiterated RatingBuyN/A
11/7/2016BMO Capital MarketsReiterated RatingOutperform$40.00N/A
11/4/2016JMP SecuritiesReiterated RatingBuyN/A
9/9/2016JMP SecuritiesReiterated RatingOutperform$28.00N/A
9/8/2016BMO Capital MarketsReiterated RatingOutperform$28.00 ➝ $40.00N/A
9/7/2016SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $32.00N/A
8/8/2016BMO Capital MarketsReiterated RatingOutperform$25.00 ➝ $28.00N/A
(Data available from 7/25/2016 forward)
Travere Therapeutics logo
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $13.23
Low: $12.75
High: $13.35

50 Day Range

MA: $26.56
Low: $24.25
High: $28.18

52 Week Range

Now: $13.23
Low: $8.98
High: $24.96

Volume

511,621 shs

Average Volume

412,277 shs

Market Capitalization

$675.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RTRX.

What is the current price target for Travere Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. Their average twelve-month price target is $29.25, suggesting a possible upside of 121.1%. BMO Capital Markets has the highest price target set, predicting RTRX will reach $33.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $21.00 for Travere Therapeutics in the next year.
View the latest price targets for RTRX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RTRX will outperform the market and that investors should add to their positions of Travere Therapeutics.
View the latest ratings for RTRX.

What other companies compete with Travere Therapeutics?

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected] The official website for Travere Therapeutics is www.retrophin.com.